Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
In this exclusive MedPage Today video, Jorge Nieva, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles, discusses the growing trend of subcutaneous formulations ...
Merck has talked up the value of its subcutaneous version of Keytruda, arguing that the investigational therapy will increase access to treatment by untethering patients from infusion centers. Roche ...
Roche' Tecentriq Subcutaneous Approved In Great Britain For All Indications Of Intravenous Tecentriq
(RTTNews) - Roche (RHHBY) said that its Tecentriq subcutaneous is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung, bladder, breast and liver ...
A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Argenx’s subcutaneous formulation of the active ingredient in Vyvgart has hit the primary endpoint in a phase 3 trial, clearing the biotech to file for approval of a product it expects to become the ...
The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...
Switching from established intravenous (IV) therapy to subcutaneous infliximab was associated with high treatment persistence, stable clinical disease activity, and consistent faecal calprotectin ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...
Please provide your email address to receive an email when new articles are posted on . Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results